Fiona E. Ralley
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Research Interests
Fiona E. Ralley has a total of 9 co-authors. Here are the top co-authors by number of shared publications:
- Alejandro Lazo-Langner
Schulich School of Medicine and Dentistry, Western University, London, ON, Canada
1 shared publication - Anargyros Xenocostas
Division of Hematology, Department of Medicine, Western University, London Health Sciences—Victoria Hospital, London, ON N6A 4V2, Canada
1 shared publication - Cyrus C. Hsia
Schulich School of Medicine & Dentistry, Department of Pathology and Laboratory Medicine, London Health Sciences Centre Western University London Ontario Canada
1 shared publication - Fatimah Al-Ani
Department of Medicine, Division of Hematology, Western University, London, ON, Canada
1 shared publication - Ian H. Chin-Yee
Division of Hematology, Department of Medicine, Schulich School of Medicine & Dentistry, Western University, London, Canada
1 shared publication - Janet Martin
Departments of Anesthesia & Perioperative Medicine and Epidemiology & Biostatistics, Western University , Ontario , Canada
1 shared publication
Latest Publications
- Open Access
- 11 March 2016
- Published by Springer Nature in BMC Hematology
- Vol. 16 (1) , 1-8
Randomized double-blind safety comparison of intravenous iron dextran versus iron sucrose in an adult non-hemodialysis outpatient population: A feasibility study
Intravenous iron therapy is a treatment option for iron deficient patients who are intolerant to oral iron or where oral iron is ineffective, but with possible adverse effects. Currently, prospective studies comparing different intravenous iron formulations are needed to determine safety and efficacy of these agents. We conducted a prospective, double-blind, randomized controlled trial (RCT) to assess the feasibility of a trial comparing the safety of high molecular weight intravenous iron dextran, Infufer®, with intravenous iron sucrose, Venofer®, in non-hemodialysis adult outpatients. Primary outcome was the occurrence of immediate severe drug reactions. We enrolled 143 patients in a one-year period. Overall, 45/143 (31.5 %) patients (20 iron dextran, 25 iron sucrose) developed 48 infusion reactions (14 immediate, 28 delayed, and 3 both). The risk of an immediate reaction was similar in both groups, 9/73 (12.3 %) iron dextran versus 8/70 (11.4 %) iron sucrose, RR = 0.93 (95 % CI; 0.38 to 2.27). The risk of a delayed reaction was significantly higher in the iron sucrose group 22/70 (31.4 %) versus the iron dextran group 9/73 (12.3 %), RR = 2.55 (95 % CI; 1.26 to 5.15; p = 0.0078). In this limited feasibility study, no major differences in immediate reactions were seen, but a significantly higher number of delayed reactions were seen in the iron sucrose group. Further, under our assumptions and design a full RCT to evaluate the safety of different intravenous iron preparations is not feasible. Future studies should consider modifying the clinical outcomes, utilize multiple centers, and consider other emerging parenteral iron formulations. (ClinicalTrials.gov NCT005936197 January 3, 2008).
- 11 March 2016
- Published by Springer Nature in BMC Hematology
- Vol. 16 (1) , 1-8
Open AccessRandomized double-blind safety comparison of intravenous iron dextran versus iron sucrose in an adult non-hemodialysis outpatient population: A feasibility study
Intravenous iron therapy is a treatment option for iron deficient patients who are intolerant to oral iron or where oral iron is ineffective, but with possible adverse effects. Currently, prospective studies comparing different intravenous iron formulations are needed to determine safety and efficacy of these agents. We conducted a prospective, double-blind, randomized controlled trial (RCT) to assess the feasibility of a trial comparing the safety of high molecular weight intravenous iron dextran, Infufer®, with intravenous iron sucrose, Venofer®, in non-hemodialysis adult outpatients. Primary outcome was the occurrence of immediate severe drug reactions. We enrolled 143 patients in a one-year period. Overall, 45/143 (31.5 %) patients (20 iron dextran, 25 iron sucrose) developed 48 infusion reactions (14 immediate, 28 delayed, and 3 both). The risk of an immediate reaction was similar in both groups, 9/73 (12.3 %) iron dextran versus 8/70 (11.4 %) iron sucrose, RR = 0.93 (95 % CI; 0.38 to 2.27). The risk of a delayed reaction was significantly higher in the iron sucrose group 22/70 (31.4 %) versus the iron dextran group 9/73 (12.3 %), RR = 2.55 (95 % CI; 1.26 to 5.15; p = 0.0078). In this limited feasibility study, no major differences in immediate reactions were seen, but a significantly higher number of delayed reactions were seen in the iron sucrose group. Further, under our assumptions and design a full RCT to evaluate the safety of different intravenous iron preparations is not feasible. Future studies should consider modifying the clinical outcomes, utilize multiple centers, and consider other emerging parenteral iron formulations. (ClinicalTrials.gov NCT005936197 January 3, 2008).
- 1 February 2014
- Published by Elsevier in Transfusion and Apheresis Science
- Vol. 50 (1) , 16-19
Erythropoietin and intravenous iron in PBM
- 1 February 2014
- Published by Elsevier in Transfusion and Apheresis Science
- Vol. 50 (1) , 16-19
Erythropoietin and intravenous iron in PBM